RA
ORKA

Royce & Associates’s Oruka Therapeutics ORKA Stock Holding History

Royce & Associates’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,510
Closed -$163K – 1262
2018
Q1 		$163K Buy
1,510
+6
+0.4% +$1.61K ﹤0.01% 1094
2017
Q4 		$447K Buy
1,504
+417
+38% +$121K ﹤0.01% 1048
2017
Q3 		$258K Buy
1,087
+254
+30% +$90.3K ﹤0.01% 1061
2017
Q2 		$441K Buy
833
+689
+478% +$359K ﹤0.01% 1044
2017
Q1 		$78K Buy
+144
New +$80.4K ﹤0.01% 1102
2016
Q4 		– Sell
-582
Closed -$363K – 1112
2016
Q3 		$363K Sell
582
-125
-18% -$80.6K ﹤0.01% 1017
2016
Q2 		$443K Sell
707
-125
-15% -$92.5K ﹤0.01% 1000
2016
Q1 		$617K Buy
+832
New +$677K ﹤0.01% 966

Other funds holding ORKA

TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACP
Aveo Capital Partners Englewood, Colorado $601M AUM 5.92% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $77.3B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return